A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom
ELECTRIC
Qualitative, Cross-sectional Observational Study Exploring the Experience of Patients Prescribed Venetoclax+Rituximab or Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in Clinical Practice in the UK
1 other identifier
observational
56
1 country
10
Brief Summary
Chronic lymphocytic leukemia (CLL), a form of Non-Hodgkin's Lymphoma, is the most common type of leukemia in adults, affecting approximately 3,800 people in the UK each year. This study will evaluate the patient experience of CLL in adult participants who are prescribed venetoclax+rituximab or Bruton's tyrosine kinase inhibitors in the United Kingdom (UK). Venetoclax+rituximab is a drug approved to treat CLL. Study participants will receive venetoclax+rituximab as prescribed by their study doctor in accordance with approved local label. Adult participants prescribed venetoclax+rituximab or Bruton's tyrosine kinase inhibitors will be enrolled. Around 140 participants will be enrolled in the study in approximately 10 sites in the UK. Participants will receive venetoclax tablets to be taken by mouth and rituximab intravenous (IV) injection according to the approved local label. There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Dec 2022
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 23, 2022
CompletedFirst Posted
Study publicly available on registry
September 27, 2022
CompletedStudy Start
First participant enrolled
December 14, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 10, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
April 10, 2024
CompletedJune 29, 2025
June 1, 2025
1.3 years
September 23, 2022
June 26, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Participants with a Change in Chronic Lymphocytic Leukemia (CLL) Symptoms
Number of participants who report a change in CLL symptoms through qualitative interviews.
Day 1
Study Arms (1)
Chronic Lymphocytic Leukemia (CLL) Participants
Participants treated with venetoclax+rituximab or bruton's tyrosine kinase inhibitors in accordance with approved local label.
Eligibility Criteria
Adult participants with second-line (2L) chronic lymphocytic leukemia (CLL) treated with venetoclax+rituximab or bruton's tyrosine kinase inhibitors per approved local label in the United Kingdom.
You may qualify if:
- Has a confirmed diagnosis of chronic lymphocytic leukemia (CLL) (as defined by 2008 Modified International Workshop for Chronic Lymphocytic Leukemia National Cancer Institute Working Group (IWCLL NCI-WG) Guidelines).
- Has relapsed/refractory (R/R) disease having received only 1 prior line of treatment, which must have been a chemotherapy or chemoimmunotherapy treatment.
You may not qualify if:
- Previously treated with a BTKi, a BCL-2 inhibitor or other investigational agents.
- Has any other medical condition or disorder that, in the opinion of the site investigator or study director, could compromise participant's ability to give written informed consent and/or prevent or interfere with his or her ability to comply with study procedures and provide meaningful information about his or her CLL experience.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AbbVielead
Study Sites (10)
Barts Health NHS Trust /ID# 252717
London, London, City of, E1 2ES, United Kingdom
Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 252720
Norwich, Norfolk, NR4 7UY, United Kingdom
Nottingham City Hospital /ID# 252716
Nottingham, Nottinghamshire, NG5 1PB, United Kingdom
Oxford University Hospitals NHS Foundation Trust /ID# 252715
Oxford, Oxfordshire, OX3 9DU, United Kingdom
University Hospitals Sussex NHS Foundation Trust /ID# 252672
Worthing, West Sussex, BN11 2DH, United Kingdom
University Hospitals of Leicester NHS Trust /ID# 252719
Leicester, LE1 5WW, United Kingdom
The Royal Marsden NHS Foundation Trust /ID# 252655
London, SW3 6JJ, United Kingdom
Portsmouth Hospitals University NHS Trust /ID# 252722
Portsmouth, PO6 3LY, United Kingdom
Sunderland Royal Hospital /ID# 252495
Sunderland, SR4 7TN, United Kingdom
Taunton and Somerset NHS Foundation Trust /ID# 252721
Taunton, TA1 5DA, United Kingdom
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
ABBVIE INC.
AbbVie
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 23, 2022
First Posted
September 27, 2022
Study Start
December 14, 2022
Primary Completion
April 10, 2024
Study Completion
April 10, 2024
Last Updated
June 29, 2025
Record last verified: 2025-06